Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Medulloblastoma - Overview Medulloblastoma - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Medulloblastoma - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Medulloblastoma - Companies Involved in Therapeutics Development Bayer AG Bristol-Myers Squibb Company DelMar Pharmaceuticals Inc Ignyta Inc IMPACT Therapeutics Inc Lipocure Ltd MacroGenics Inc NewLink Genetics Corp Novogen Ltd Ono Pharmaceutical Co Ltd Progenics Pharmaceuticals Inc Stemline Therapeutics Inc ThromboGenics NV VBI Vaccines Inc Medulloblastoma - Drug Profiles (topotecan hydrochloride + vincristine sulfate) - Drug Profile Product Description Mechanism Of Action R&D Progress Bispecific Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile Product Description Mechanism Of Action R&D Progress Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress dianhydrogalactitol - Drug Profile Product Description Mechanism Of Action R&D Progress Edotreotide Labeled Yttrium 90 - Drug Profile Product Description Mechanism Of Action R&D Progress IMP-5471 - Drug Profile Product Description Mechanism Of Action R&D Progress indoximod - Drug Profile Product Description Mechanism Of Action R&D Progress ipilimumab + nivolumab - Drug Profile Product Description Mechanism Of Action R&D Progress irinotecan hydrochloride + TBio-02 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-5 - Drug Profile Product Description Mechanism Of Action R&D Progress nifurtimox - Drug Profile Product Description Mechanism Of Action R&D Progress nifurtimox SR - Drug Profile Product Description Mechanism Of Action R&D Progress nivolumab - Drug Profile R&D Progress Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile Product Description Mechanism Of Action R&D Progress p28 - Drug Profile Product Description Mechanism Of Action R&D Progress pyrvinium pamoate - Drug Profile Product Description Mechanism Of Action R&D Progress SL-301 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile Product Description Mechanism Of Action R&D Progress taladegib - Drug Profile Product Description Mechanism Of Action R&D Progress THR-317 - Drug Profile Product Description Mechanism Of Action R&D Progress Trilexium - Drug Profile Product Description Mechanism Of Action R&D Progress VBI-1901 - Drug Profile Product Description Mechanism Of Action R&D Progress VIMO-001 - Drug Profile Product Description Mechanism Of Action R&D Progress VMY-1103 - Drug Profile Product Description Mechanism Of Action R&D Progress Medulloblastoma - Dormant Projects Medulloblastoma - Product Development Milestones Featured News & Press Releases Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Medulloblastoma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Medulloblastoma - Pipeline by Bayer AG, H1 2017 Medulloblastoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017 Medulloblastoma - Pipeline by Ignyta Inc, H1 2017 Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H1 2017 Medulloblastoma - Pipeline by Lipocure Ltd, H1 2017 Medulloblastoma - Pipeline by MacroGenics Inc, H1 2017 Medulloblastoma - Pipeline by NewLink Genetics Corp, H1 2017 Medulloblastoma - Pipeline by Novogen Ltd, H1 2017 Medulloblastoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017 Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H1 2017 Medulloblastoma - Pipeline by ThromboGenics NV, H1 2017 Medulloblastoma - Pipeline by VBI Vaccines Inc, H1 2017 Medulloblastoma - Dormant Projects, H1 2017 List of Figures Number of Products under Development for Medulloblastoma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products by Top 10 Targets, H1 2017 Number of Products by Stage and Top 10 Targets, H1 2017 Number of Products by Top 10 Mechanism of Actions, H1 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 Number of Products by Routes of Administration, H1 2017 Number of Products by Stage and Routes of Administration, H1 2017 Number of Products by Molecule Types, H1 2017 Number of Products by Stage and Molecule Types, H1 2017

Bayer AG Bristol-Myers Squibb Company DelMar Pharmaceuticals Inc Ignyta Inc IMPACT Therapeutics Inc Lipocure Ltd MacroGenics Inc NewLink Genetics Corp Novogen Ltd Ono Pharmaceutical Co Ltd Progenics Pharmaceuticals Inc Stemline Therapeutics Inc ThromboGenics NV VBI Vaccines Inc